Physician profile
Thomas E Gribbin
NPI 1639179286
$2,739.01
in general payments reported to CMS, 2019-2025
31 companies · $1,877 in 2025
The $1,877 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $261 · 2020: $20.54 · 2021: $11.92 · 2022: $74.59 · 2023: $209 · 2024: $285 · 2025: $1,877.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,220 · Education: $152.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,219.64 |
| Education | $151.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $341.45 | 2019-2025 | Enhertu, Imfinzi, Onglyza |
| Merck Sharp & Dohme LLC | $325.82 | 2023-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Novartis Pharmaceuticals Corporation | $322.63 | 2024-2025 | |
| Glaxosmithkline, LLC. | $239.49 | 2024-2025 | Ojjaara, Blenrep |
| Foundation Medicine, INC. | $148.90 | 2019 | |
| Gilead Sciences, INC. | $135.58 | 2021-2025 | Trodelvy |
| Pfizer INC. | $133.96 | 2022-2025 | |
| Geron Corporation | $111.48 | 2025 | Rytelo |
| Genentech USA, INC. | $77.77 | 2025 | Itovebi |
| Genzyme Corporation | $75.91 | 2025 | |
| Beone Medicines USA, INC. | $74.88 | 2025 | Tevimbra, Brukinsa |
| Regeneron Healthcare Solutions, INC. | $74.75 | 2024-2025 | Libtayo |
| Pharmacyclics LLC, An Abbvie Company | $67.06 | 2022-2023 | Imbruvica |
| Abbvie INC. | $60.70 | 2023-2025 | |
| Amneal Pharmaceuticals LLC | $56.56 | 2024-2025 | Avastin, Alymsys |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Array Biopharma INC | $56.39 | 2024-2025 | Mektovi, Braftovi, Tukysa |
| Ipsen Biopharmaceuticals, INC | $54.28 | 2025 | Onivyde |
| Caris Mpi, INC. | $51.77 | 2025 | Mi Cancer Seek |
| Daiichi Sankyo INC. | $50.16 | 2025 | Datroway, Enhertu |
| E.R. Squibb & Sons, L.L.C. | $39.39 | 2019-2025 | Opdualag |
| Kyowa Kirin, INC. | $28.66 | 2022-2025 | |
| Incyte Corporation | $28.34 | 2025 | Monjuvi, Zynyz |
| Sobi, INC | $24.57 | 2025 | |
| Agios Pharmaceuticals, INC. | $23.08 | 2025 | Pyrukynd |
| Stemline Therapeutics INC. | $21.51 | 2024 | Orserdu |
| Adaptive Biotechnologies Corporation | $20.54 | 2020 | |
| Pharmaessentia USA Corporation | $20.11 | 2024 | Besremi |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| Celgene Corporation | $18.24 | 2024 | Reblozyl |
| Pharmacosmos Therapeutics INC. | $17.54 | 2025 | Monoferric |
| Emd Serono, INC. | $17.49 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Gribbin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.